General Information of Drug Transporter (DT)
DT ID	DTD0001 Transporter Info
Gene Name	ABCC1
Protein Name	Multidrug resistance-associated protein 1
Gene ID	4363
UniProt ID	P33527
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs119774
Site of GPD	chr16:15992976 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.0391/196 (Global)
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Montelukast	Drug Info	Asthma	Correlated with the increased changes in FEV1 in patients (compare with genotype CC)		[ 1]
Montelukast	N.A.	Drug-induced Liver Injury	Genotype CT is associated with increased changes in FEV1 when treated with montelukast in people with Asthma as compared to genotype CC.		[ 1]
Montelukast	N.A.	Asthma	Genotype CT is associated with increased changes in FEV1 when treated with montelukast in people with Asthma as compared to genotype CC.		[ 1]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Montelukast	N.A.	Asthma	Patients with the CC genotype and Asthma may not have an increased response to montelukast treatment, based on no change in Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.		[ 1]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Montelukast	N.A.	Asthma	Patients with the TT genotype were not studied. But patients with the CT genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.		[ 1]
Genetic Polymorphism	rs4148350
Site of GPD	chr16:16076620 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>T
Minor Allele Frequency	T=0.0681/341 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           8 Drugs in Total
Daunorubicin	Drug Info	Neoplasm	Irrelevant to the likelihood of cardiotoxicity in patients (compare with allele G)		[ 2]
Doxorubicin	Drug Info	Neoplasm	Irrelevant to the likelihood of cardiotoxicity in patients (compare with allele G)		[ 2]
Anthracyclines And Related Substances	N.A.	Adverse Events	Allele T is associated with increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele G.		[ 3]
Daunorubicin	N.A.	Cardiotoxicity	Allele T is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.		[ 2]
Doxorubicin	N.A.	Cardiotoxicity	Allele T is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.		[ 2]
Anthracyclines And Related Substances	N.A.	Neoplasms	Allele T is associated with increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele G.		[ 3]
Anthracyclines And Related Substances	N.A.	Neoplasms	Allele T is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.		[ 2]
Anthracyclines	N.A.	Neoplasm	Correlated with the increased likelihood of cardiotoxicity in patients (compare with allele G)		[ 3]
Genotypes GT + TT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cyclophosphamide	N.A.	Drug Toxicity	Genotypes GT + TT is not associated with risk of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype GG.		[ 4]
Doxorubicin	N.A.	Drug Toxicity	Genotypes GT + TT is not associated with risk of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype GG.		[ 4]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cyclophosphamide	N.A.	Toxic Liver Disease	Genotype GG is not associated with increased response to cyclophosphamide in people with Lupus Nephritis as compared to genotype GT.		[ 5]
Anthracyclines And Related Substances	N.A.	Neoplasms	Patients with the GG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GT or TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.		[ 3]
Genotype GT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Anthracyclines And Related Substances	N.A.	Neoplasms	Patients with the GT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the TT genotype and increased likelihood as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.		[ 3]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Anthracyclines And Related Substances	N.A.	Neoplasms	Patients with the TT genotype may have an increased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GT or GG genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.		[ 3]
Genetic Polymorphism	rs45511401
Site of GPD	chr16:16079375 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>T
Minor Allele Frequency	T=0.0154/77 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Doxorubicin	Drug Info	Non-Hodgkin Lymphoma	Correlated with the increased cardiotoxicity risk in patients (compare with allele G)		[ 6]
Doxorubicin	N.A.	Drug-induced Liver Injury	Allele T is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele G.		[ 6]
Doxorubicin	N.A.	Cardiac Rhythm Disease	Allele T is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele G.		[ 6]
Doxorubicin	N.A.	Drug Toxicity	Allele T is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele G.		[ 6]
Doxorubicin	N.A.	Non-hodgkin Lymphoma	Allele T is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele G.		[ 6]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Doxorubicin	N.A.	Cardiac Rhythm Disease	Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.		[ 6]
Doxorubicin	N.A.	Drug Toxicity	Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.		[ 6]
Doxorubicin	N.A.	Non-hodgkin Lymphoma	Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.		[ 6]
Genotype GT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Doxorubicin	N.A.	Cardiac Rhythm Disease	Patients with the GT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype or may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.		[ 6]
Doxorubicin	N.A.	Drug Toxicity	Patients with the GT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype or may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.		[ 6]
Doxorubicin	N.A.	Non-hodgkin Lymphoma	Patients with the GT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype or may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.		[ 6]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Doxorubicin	N.A.	Cardiac Rhythm Disease	Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.		[ 6]
Doxorubicin	N.A.	Drug Toxicity	Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.		[ 6]
Doxorubicin	N.A.	Non-hodgkin Lymphoma	Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.		[ 6]
Genetic Polymorphism	rs35592
Site of GPD	chr16:16047966 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	C=0.3704/1855 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           7 Drugs in Total
Methotrexate	Drug Info	Rheumatoid Arthritis	Irrelevant to the drug response in patients (compare with Allele T)		[ 7]
Methotrexate	N.A.	Drug Toxicity	Allele C is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele T.		[ 7]
Methotrexate	N.A.	Lymphopenia	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.		[ 8]
Antineoplastic Agents	N.A.	Drug Toxicity	Allele C is not associated with risk of Drug Toxicity when treated with antineoplastic agents and corticosteroids in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 9]
Corticosteroids	N.A.	Drug Toxicity	Allele C is not associated with risk of Drug Toxicity when treated with antineoplastic agents and corticosteroids in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 9]
Methotrexate	N.A.	Psoriasis	Allele C is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele T.		[ 7]
Methotrexate	N.A.	Rheumatoid Arthritis	Allele C is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele T.		[ 7]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Methotrexate	Drug Info	Psoriasis	Correlated with the increased drug response in patients (compare with genotypes CC + CT)		[ 10]
Methotrexate	N.A.	Anemia	Genotype TT is associated with increased response to methotrexate in people with Psoriasis as compared to genotypes CC + CT.		[ 10]
Methotrexate	N.A.	Psoriasis	Genotype TT is associated with increased response to methotrexate in people with Psoriasis as compared to genotypes CC + CT.		[ 10]
Methotrexate	N.A.	Rheumatoid Arthritis	Genotype TT is associated with increased response to methotrexate in people with Psoriasis as compared to genotypes CC + CT.		[ 10]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methotrexate	N.A.	Psoriasis	Patients with the CC genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the TT genotype. There is no association with response to rheumatoid arthritis. Other genetic and clinical factors may also influence a patient's response to methotrexate.		[ 10]
Methotrexate	N.A.	Rheumatoid Arthritis	Patients with the CC genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the TT genotype. There is no association with response to rheumatoid arthritis. Other genetic and clinical factors may also influence a patient's response to methotrexate.		[ 10]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methotrexate	N.A.	Psoriasis	Patients with the CT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the TT genotype. There is no association with response to rheumatoid arthritis. Other genetic and clinical factors may also influence a patient's response to methotrexate.		[ 10]
Methotrexate	N.A.	Rheumatoid Arthritis	Patients with the CT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the TT genotype. There is no association with response to rheumatoid arthritis. Other genetic and clinical factors may also influence a patient's response to methotrexate.		[ 10]
Genetic Polymorphism	rs17501331
Site of GPD	chr16:15995584 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	G=0.0383/192 (Global)
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Irinotecan	Drug Info	Colorectal Neoplasm	Correlated with the decreased severity of neutropenia in patients (compare with genotype AA)		[ 11]
Irinotecan	N.A.	Neutropenia	Genotypes AG + GG are associated with decreased severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype AA.		[ 11]
Irinotecan	N.A.	Colorectal Neoplasms	Genotypes AG + GG are associated with decreased severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype AA.		[ 11]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the AA genotype and colorectal neoplasms may have increased severity of neutropenia compared to patients with the AG and GG genotypes when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.		[ 11]
Irinotecan	N.A.	Neutropenia	Patients with the AA genotype and colorectal neoplasms may have increased severity of neutropenia compared to patients with the AG and GG genotypes when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.		[ 11]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the AG genotype and colorectal neoplasms may have decreased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.		[ 11]
Irinotecan	N.A.	Neutropenia	Patients with the AG genotype and colorectal neoplasms may have decreased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.		[ 11]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the GG genotype and colorectal neoplasms may have decreased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.		[ 11]
Irinotecan	N.A.	Neutropenia	Patients with the GG genotype and colorectal neoplasms may have decreased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.		[ 11]
Genetic Polymorphism	rs212091
Site of GPD	chr16:16142793 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C
Minor Allele Frequency	C=0.1360/681 (Global)
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:         12 Drugs in Total
Lamivudine	Drug Info	HIV Infection	Correlated with the increased drug resistance in patients (compare with Genotype TT)		[ 12]
Lopinavir	Drug Info	HIV Infection	Correlated with the increased drug resistance in patients (compare with Genotype TT)		[ 12]
Zidovudine	Drug Info	HIV Infection	Correlated with the increased drug resistance in patients (compare with Genotype TT)		[ 12]
Ritonavir	Drug Info	HIV Infection	Correlated with the increased drug resistance in patients (compare with Genotype TT)		[ 12]
Lamivudine	N.A.	Neurotoxicity Syndromes	Genotypes CC + CT are associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV Infections as compared to genotype TT.		[ 12]
Lopinavir	N.A.	Neurotoxicity Syndromes	Genotypes CC + CT are associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV Infections as compared to genotype TT.		[ 12]
Ritonavir	N.A.	Neurotoxicity Syndromes	Genotypes CC + CT are associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV Infections as compared to genotype TT.		[ 12]
Zidovudine	N.A.	Neurotoxicity Syndromes	Genotypes CC + CT are associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV Infections as compared to genotype TT.		[ 12]
Lamivudine	N.A.	HIV Infectious Disease	Genotypes CC + CT are associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV Infections as compared to genotype TT.		[ 12]
Lopinavir	N.A.	HIV Infectious Disease	Genotypes CC + CT are associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV Infections as compared to genotype TT.		[ 12]
Ritonavir	N.A.	HIV Infectious Disease	Genotypes CC + CT are associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV Infections as compared to genotype TT.		[ 12]
Zidovudine	N.A.	HIV Infectious Disease	Genotypes CC + CT are associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV Infections as compared to genotype TT.		[ 12]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Lamivudine	N.A.	HIV Infectious Disease	Patients with the CC genotype and HIV may have an increased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for virological failure.		[ 12]
Lopinavir	N.A.	HIV Infectious Disease	Patients with the CC genotype and HIV may have an increased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for virological failure.		[ 12]
Ritonavir	N.A.	HIV Infectious Disease	Patients with the CC genotype and HIV may have an increased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for virological failure.		[ 12]
Zidovudine	N.A.	HIV Infectious Disease	Patients with the CC genotype and HIV may have an increased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for virological failure.		[ 12]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Lamivudine	N.A.	HIV Infectious Disease	Patients with the CT genotype and HIV may have an increased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for virological failure.		[ 12]
Lopinavir	N.A.	HIV Infectious Disease	Patients with the CT genotype and HIV may have an increased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for virological failure.		[ 12]
Ritonavir	N.A.	HIV Infectious Disease	Patients with the CT genotype and HIV may have an increased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for virological failure.		[ 12]
Zidovudine	N.A.	HIV Infectious Disease	Patients with the CT genotype and HIV may have an increased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for virological failure.		[ 12]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Lamivudine	N.A.	HIV Infectious Disease	Patients with the TT genotype and HIV may have a decreased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for virological failure.		[ 12]
Lopinavir	N.A.	HIV Infectious Disease	Patients with the TT genotype and HIV may have a decreased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for virological failure.		[ 12]
Ritonavir	N.A.	HIV Infectious Disease	Patients with the TT genotype and HIV may have a decreased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for virological failure.		[ 12]
Zidovudine	N.A.	HIV Infectious Disease	Patients with the TT genotype and HIV may have a decreased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for virological failure.		[ 12]
Genetic Polymorphism	rs2238476
Site of GPD	chr16:16120015 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.0691/346 (Global)
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Methotrexate	Drug Info	Psoriasis	Correlated with the increased drug response in patients (compare with allele A); Correlated with the increased toxicity risk in patients (compare with genotypes AA + AG)		[ 10]
Methotrexate	N.A.	Drug-induced Liver Injury	Genotype GG is associated with increased response to methotrexate in people with Psoriasis as compared to allele A.		[ 10]
Methotrexate	N.A.	Psoriasis	Genotype GG is associated with increased response to methotrexate in people with Psoriasis as compared to allele A.		[ 10]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methotrexate	N.A.	Adverse Events	Genotype AG is associated with increased likelihood of adverse events when treated with methotrexate in people with Psoriasis as compared to genotype GG.		[ 13]
Methotrexate	N.A.	Psoriasis	Patients with the AG genotype and psoriasis who are treated with methotrexate: 1) may be less likely to have a reduction in psoriasis area or disease severity 2) may have a reduced, but not absent, risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity.		[ 10]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Psoriasis	Patients with the AA genotype and psoriasis who are treated with methotrexate: 1) may be less likely to have a reduction in psoriasis area or disease severity 2) may have a reduced, but not absent risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity.		[ 10]
Genetic Polymorphism	rs246240
Site of GPD	chr16:16025167 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	G=0.1827/915 (Global)
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Methotrexate	Drug Info	Rheumatoid Arthritis	Correlated with the decreased drug response in patients (compare with genotype AA)		[ 14]
Methotrexate	N.A.	Drug-induced Liver Injury	Genotypes AG + GG are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA.		[ 14]
Methotrexate	N.A.	Anemia	Genotypes AG + GG are associated with decreased risk of onset of toxicity when treated with methotrexate in people with Psoriasis as compared to genotype AA.		[ 10]
Methotrexate	N.A.	Drug Toxicity	Genotypes AG + GG are associated with decreased risk of onset of toxicity when treated with methotrexate in people with Psoriasis as compared to genotype AA.		[ 10]
Methotrexate	N.A.	Psoriasis	Genotypes AG + GG are associated with decreased risk of onset of toxicity when treated with methotrexate in people with Psoriasis as compared to genotype AA.		[ 10]
Methotrexate	N.A.	Rheumatoid Arthritis	Genotypes AG + GG are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA.		[ 14]
Genotypes GG + AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	Drug Info	Psoriasis	Correlated with the decreased onset of toxicity risk in patients (compare with genotype AA)		[ 10]
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Lymphopenia	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.		[ 8]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Antineoplastic Agents	N.A.	Neurotoxicity Syndromes	Genotype GG is associated with increased risk of Neurotoxicity Syndromes when treated with antineoplastic agents and corticosteroids in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.		[ 9]
Corticosteroids	N.A.	Neurotoxicity Syndromes	Genotype GG is associated with increased risk of Neurotoxicity Syndromes when treated with antineoplastic agents and corticosteroids in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.		[ 9]
Methotrexate	N.A.	Drug Toxicity	Patients with the GG genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity to methotrexate.		[ 10]
Methotrexate	N.A.	Psoriasis	Patients with the GG genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity to methotrexate.		[ 10]
Methotrexate	N.A.	Rheumatoid Arthritis	Patients with the GG genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate.		[ 14]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Methotrexate	N.A.	Drug Toxicity	Patients with the AA genotype and psoriasis who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity to methotrexate.		[ 10]
Methotrexate	N.A.	Psoriasis	Patients with the AA genotype and psoriasis who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity to methotrexate.		[ 10]
Methotrexate	N.A.	Rheumatoid Arthritis	Patients with the AA genotype may have increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG or AG. Other genetic and clinical factors may also influence the response to methotrexate.		[ 14]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Methotrexate	N.A.	Drug Toxicity	Patients with the AG genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity to methotrexate.		[ 10]
Methotrexate	N.A.	Psoriasis	Patients with the AG genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity to methotrexate.		[ 10]
Methotrexate	N.A.	Rheumatoid Arthritis	Patients with the AG genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate.		[ 14]
Genetic Polymorphism	rs28364006
Site of GPD	chr16:16134392 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Methotrexate	Drug Info	Psoriasis	Correlated with the increased drug response in patients (compare with allele AG)		[ 10]
Methotrexate	N.A.	Overall Survival	Genotype GG is associated with increased response to methotrexate in people with Psoriasis as compared to genotype AG.		[ 10]
Methotrexate	N.A.	Psoriasis	Genotype GG is associated with increased response to methotrexate in people with Psoriasis as compared to genotype AG.		[ 10]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Psoriasis	Patients with the AA genotype were not studied, and so conclusions cannot be made in regard to response to methotrexate. However, patients with the GA genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.		[ 10]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Psoriasis	Patients with the GA genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.		[ 10]
Genetic Polymorphism	rs35621
Site of GPD	chr16:16074751 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.1248/625 (Global)
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Sn-38	Drug Info	Colorectal Neoplasm	Correlated with the increased drug exposure in patients (compare with genotype CC)		[ 11]
SN-38	N.A.	Neurotoxicity Syndromes	Genotypes CT + TT are associated with increased exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype CC.		[ 11]
SN-38	N.A.	Colorectal Neoplasms	Genotypes CT + TT are associated with increased exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype CC.		[ 11]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
SN-38	N.A.	Colorectal Neoplasms	Patients with the CC genotype and colorectal neoplasms may have decreased exposure to SN-38 compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect exposure to SN-38.		[ 11]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
SN-38	N.A.	Colorectal Neoplasms	Patients with the CT genotype and colorectal neoplasms may have increased exposure to SN-38 compared to patients with the CC genotype. Other clinical and genetic factors may affect exposure to SN-38.		[ 11]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
SN-38	N.A.	Colorectal Neoplasms	Patients with the TT genotype and colorectal neoplasms may have increased exposure to SN-38 compared to patients with the CC genotype. Other clinical and genetic factors may affect exposure to SN-38.		[ 11]
Genetic Polymorphism	rs3743527
Site of GPD	chr16:16141824 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.2943/1474 (Global)
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Irinotecan	Drug Info	Colorectal Neoplasm	Correlated with the decreased severity of neutropenia in patients (compare with genotype CC)		[ 11]
Irinotecan	N.A.	Neutropenia	Genotypes CT + TT are associated with decreased severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype CC.		[ 11]
SN-38	N.A.	Cardiotoxicity	Genotypes CT + TT are not associated with exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype CC.		[ 11]
Irinotecan	N.A.	Colorectal Neoplasms	Genotypes CT + TT are associated with decreased severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype CC.		[ 11]
Allele T	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Lamivudine	N.A.	Graft Vs Host Disease	Allele T is not associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV Infections as compared to allele C.		[ 12]
Lopinavir	N.A.	Graft Vs Host Disease	Allele T is not associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV Infections as compared to allele C.		[ 12]
Ritonavir	N.A.	Graft Vs Host Disease	Allele T is not associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV Infections as compared to allele C.		[ 12]
Zidovudine	N.A.	Graft Vs Host Disease	Allele T is not associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV Infections as compared to allele C.		[ 12]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the CC genotype and colorectal neoplasms may have increased severity of neutropenia when taking irinotecan compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.		[ 11]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the CT genotype and colorectal neoplasms may have deceased severity of neutropenia when taking irinotecan compared to patients with the CC genotype. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.		[ 11]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the TT genotype and colorectal neoplasms may have deceased severity of neutropenia when taking irinotecan compared to patients with the CC genotype. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.		[ 11]
Genetic Polymorphism	rs3784864
Site of GPD	chr16:16031468 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.3271/1638 (Global)
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Methotrexate	Drug Info	Rheumatoid Arthritis	Correlated with the decreased drug response in patients (compare with genotype AA)		[ 14]
Methotrexate	N.A.	Drug-induced Liver Injury	Genotypes AG + GG are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA.		[ 14]
Methotrexate	N.A.	Rheumatoid Arthritis	Genotypes AG + GG are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA.		[ 14]
Allele A	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Antineoplastic Agents	N.A.	Drug Toxicity	Allele A is not associated with risk of Drug Toxicity when treated with antineoplastic agents and corticosteroids in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 9]
Corticosteroids	N.A.	Drug Toxicity	Allele A is not associated with risk of Drug Toxicity when treated with antineoplastic agents and corticosteroids in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 9]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Rheumatoid Arthritis	Patients with the AA genotype may have increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG or AG. Other genetic and clinical factors may also influence the response to methotrexate.		[ 14]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Rheumatoid Arthritis	Patients with the AG genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate.		[ 14]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Rheumatoid Arthritis	Patients with the GG genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate.		[ 14]
Genetic Polymorphism	rs6498588
Site of GPD	chr16:15938949 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>T
Minor Allele Frequency	A=0.3770/1888 (Global)
Genotypes AT + TT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Sn-38	Drug Info	Colorectal Neoplasm	Correlated with the increased drug exposure in patients (compare with genotype AA)		[ 11]
SN-38	N.A.	Neurotoxicity Syndromes	Genotypes AT + TT are associated with increased exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype AA.		[ 11]
SN-38	N.A.	Colorectal Neoplasms	Genotypes AT + TT are associated with increased exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype AA.		[ 11]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
SN-38	N.A.	Colorectal Neoplasms	Patients with the AA genotype and colorectal neoplasm may have decreased exposure to SN-38 compared to patients with the AT and TT genotypes. Other clinical and genetic factors may affect exposure to SN-38.		[ 11]
Genotype AT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
SN-38	N.A.	Colorectal Neoplasms	Patients with the AT genotype and colorectal neoplasm may have increased exposure to SN-38 compared to patients with the AA genotype. Other clinical and genetic factors may affect exposure to SN-38.		[ 11]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
SN-38	N.A.	Colorectal Neoplasms	Patients with the TT genotype and colorectal neoplasm may have increased exposure to SN-38 compared to patients with the AA genotype. Other clinical and genetic factors may affect exposure to SN-38.		[ 11]
Genetic Polymorphism	rs17264736
Site of GPD	chr16:16022699 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>T
Minor Allele Frequency	G=0.6440/1274 (Global)
Genotypes GG + GT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cyclosporine	N.A.	Graft Vs Host Disease	Genotypes GG + GT is associated with decreased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotype TT.		[ 15]
Methotrexate	N.A.	Graft Vs Host Disease	Genotypes GG + GT is associated with decreased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotype TT.		[ 15]
Genetic Polymorphism	rs4781712
Site of GPD	chr16:16009375 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G / A>T
Minor Allele Frequency	A=0.5870/1161 (Global)
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cyclosporine	N.A.	Graft Vs Host Disease	Genotypes AA + AG is associated with decreased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotype GG.		[ 15]
Methotrexate	N.A.	Graft Vs Host Disease	Genotypes AA + AG is associated with decreased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotype GG.		[ 15]
Genetic Polymorphism	rs58572178
Site of GPD	chr16:16052441 (GRCh38.p12)
GPD Type	Indel
Allele(s) in dbSNP	AAAAAAAAA / AAAAAAAAAAAA / AAAAAAAAAAAAA / AAAAAAAAAAAAAA / AAAAAAAAAAAAAAA / AAAAAAAAAAAAAAAA
Minor Allele Frequency	AAAAAAAAAAAAA=0.7620/1507 (Global)
Genotype (A)14	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Fentanyl	N.A.	Graft Vs Host Disease	Allele (A)14 is associated with increased clearance of fentanyl in children with Pain and Premature Birth as compared to allele (A)13.		[ 16]
Genetic Polymorphism	rs8058040
Site of GPD	chr16:16013855 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.7800/1543 (Global)
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cyclosporine	N.A.	Graft Vs Host Disease	Genotype AA is associated with increased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotypes AG + GG.		[ 15]
Methotrexate	N.A.	Graft Vs Host Disease	Genotype AA is associated with increased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotypes AG + GG.		[ 15]
Genetic Polymorphism	rs3784867
Site of GPD	chr16:16109488 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.7290/1442 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Vincristine	N.A.	Peripheral Nervous System Diseases	Allele T is associated with increased risk of Peripheral Nervous System Diseases when treated with vincristine as compared to allele C.		[ 17]
Genetic Polymorphism	rs2074087
Site of GPD	chr16:16090375 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>G
Minor Allele Frequency	C=0.2100/415 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Fluorouracil	N.A.	Neurotoxicity Syndromes	Allele C is associated with decreased severity of Neurotoxicity Syndromes when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to allele G.		[ 18]
Leucovorin	N.A.	Neurotoxicity Syndromes	Allele C is associated with decreased severity of Neurotoxicity Syndromes when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to allele G.		[ 18]
Oxaliplatin	N.A.	Neurotoxicity Syndromes	Allele C is associated with decreased severity of Neurotoxicity Syndromes when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to allele G.		[ 18]
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Anemia	Allele G is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 19]
Genotypes CC + CG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Azathioprine	N.A.	Lymphopenia	Genotypes CC + CG is associated with increased likelihood of Lymphopenia when treated with azathioprine in children with Inflammatory Bowel Diseases as compared to genotype GG.		[ 20]
Genetic Polymorphism	rs4148354
Site of GPD	chr16:16080649 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>T
Minor Allele Frequency	G=0.6580/1302 (Global)
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cyclophosphamide	N.A.	Drug Toxicity	Genotypes AG + GG is not associated with risk of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype AA.		[ 4]
Doxorubicin	N.A.	Drug Toxicity	Genotypes AG + GG is not associated with risk of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype AA.		[ 4]
Genetic Polymorphism	rs2889517
Site of GPD	chr16:16088099 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C
Minor Allele Frequency	T=0.4150/821 (Global)
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cyclophosphamide	N.A.	Drug Toxicity	Genotypes CT + TT is not associated with risk of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype CC.		[ 4]
Doxorubicin	N.A.	Drug Toxicity	Genotypes CT + TT is not associated with risk of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype CC.		[ 4]
Genetic Polymorphism	rs11861115
Site of GPD	chr16:16105813 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.6970/1379 (Global)
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cyclophosphamide	N.A.	Drug Toxicity	Genotypes AA + AG is not associated with risk of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype GG.		[ 4]
Doxorubicin	N.A.	Drug Toxicity	Genotypes AA + AG is not associated with risk of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype GG.		[ 4]
Genetic Polymorphism	rs16967126
Site of GPD	chr16:16034561 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.8710/1723 (Global)
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cyclophosphamide	N.A.	Drug Toxicity	Genotypes CC + CT is not associated with risk of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype TT.		[ 4]
Doxorubicin	N.A.	Drug Toxicity	Genotypes CC + CT is not associated with risk of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype TT.		[ 4]
Genetic Polymorphism	rs35596
Site of GPD	chr16:16059083 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.5970/1181 (Global)
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cyclophosphamide	N.A.	Drug Toxicity	Genotypes CC + CT is not associated with risk of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype TT.		[ 4]
Doxorubicin	N.A.	Drug Toxicity	Genotypes CC + CT is not associated with risk of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype TT.		[ 4]
Genetic Polymorphism	rs903880
Site of GPD	chr16:16036657 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A
Minor Allele Frequency	C=0.6500/1286 (Global)
Genotypes AA + AC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cyclophosphamide	N.A.	Drug Toxicity	Genotypes AA + AC is not associated with risk of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype CC.		[ 4]
Doxorubicin	N.A.	Drug Toxicity	Genotypes AA + AC is not associated with risk of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype CC.		[ 4]
Genetic Polymorphism	rs246221
Site of GPD	chr16:16044465 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.5690/1126 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Cyclophosphamide	N.A.	Drug-induced Liver Injury	Genotype CC is associated with increased likelihood of drug-induced liver injury when treated with cyclophosphamide, docetaxel and epirubicin in women with Breast Neoplasms as compared to genotypes CT + TT.		[ 21]
Docetaxel	N.A.	Drug-induced Liver Injury	Genotype CC is associated with increased likelihood of drug-induced liver injury when treated with cyclophosphamide, docetaxel and epirubicin in women with Breast Neoplasms as compared to genotypes CT + TT.		[ 21]
Epirubicin	N.A.	Drug-induced Liver Injury	Genotype CC is associated with increased likelihood of drug-induced liver injury when treated with cyclophosphamide, docetaxel and epirubicin in women with Breast Neoplasms as compared to genotypes CT + TT.		[ 21]
Cyclophosphamide	N.A.	Toxic Liver Disease	Genotype CC is not associated with increased response to cyclophosphamide in people with Lupus Nephritis as compared to genotype CT.		[ 5]
Genetic Polymorphism	rs3784862
Site of GPD	chr16:16017034 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	G=0.4070/805 (Global)
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Drug-induced Liver Injury	Genotype AA is associated with increased likelihood of toxicity when treated with methotrexate in people with Psoriasis as compared to genotypes AG + GG.		[ 10]
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Anemia	Allele A is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 19]
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Lymphopenia	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.		[ 8]
Genetic Polymorphism	rs212090
Site of GPD	chr16:16142147 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A
Minor Allele Frequency	T=0.7180/1420 (Global)
Genotypes AA + AT	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Antineoplastic And Immunomodulating Agents	N.A.	Neutropenia	Genotypes AA + AT is associated with decreased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 22]
Antineoplastic And Immunomodulating Agents	N.A.	Leukopenia	Genotypes AA + AT is associated with decreased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 22]
Antineoplastic And Immunomodulating Agents	N.A.	Thrombocytopenia	Genotypes AA + AT is associated with decreased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 22]
Antineoplastic And Immunomodulating Agents	N.A.	Anemia	Genotypes AA + AT is associated with decreased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 22]
Irinotecan	N.A.	Neutropenia	Genotypes AA + AT are not associated with severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype TT.		[ 11]
Genotypes AT + TT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Clozapine	N.A.	Hypertension	Genotypes AT + TT is associated with increased Hypertension when treated with clozapine in men with Schizophrenia as compared to genotype AA.		[ 23]
Clozapine	N.A.	Weight Gain	Genotypes AT + TT is associated with increased Weight gain when treated with clozapine in men with as compared to genotype AA.		[ 23]
Genetic Polymorphism	rs212087
Site of GPD	chr16:16136433 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.7020/1389 (Global)
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Antineoplastic And Immunomodulating Agents	N.A.	Neutropenia	Genotypes AA + AG is associated with decreased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 22]
Antineoplastic And Immunomodulating Agents	N.A.	Leukopenia	Genotypes AA + AG is associated with decreased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 22]
Antineoplastic And Immunomodulating Agents	N.A.	Thrombocytopenia	Genotypes AA + AG is associated with decreased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 22]
Antineoplastic And Immunomodulating Agents	N.A.	Anemia	Genotypes AA + AG is associated with decreased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 22]
Genetic Polymorphism	rs8050881
Site of GPD	chr16:15943404 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>G
Minor Allele Frequency	A=0.4500/890 (Global)
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Irinotecan	N.A.	Neutropenia	Genotypes AG + GG are not associated with severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype AA.		[ 11]
Genetic Polymorphism	rs129081
Site of GPD	chr16:16142082 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	G=0.4810/951 (Global)
Genotypes CC + CG	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Antineoplastic And Immunomodulating Agents	N.A.	Neutropenia	Genotypes CC + CG is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 22]
Antineoplastic And Immunomodulating Agents	N.A.	Leukopenia	Genotypes CC + CG is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 22]
Antineoplastic And Immunomodulating Agents	N.A.	Thrombocytopenia	Genotypes CC + CG is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 22]
Antineoplastic And Immunomodulating Agents	N.A.	Anemia	Genotypes CC + CG is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 22]
Genetic Polymorphism	rs2230671
Site of GPD	chr16:16134385 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.8270/1636 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Anemia	Allele A is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 19]
Genetic Polymorphism	rs215095
Site of GPD	chr16:15966537 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	G=0.1560/308 (Global)
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
SN-38	N.A.	Cardiotoxicity	Genotypes AG + GG are not associated with exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype AA.		[ 11]
Genetic Polymorphism	rs212082
Site of GPD	chr16:16133290 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.8540/1690 (Global)
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
SN-38	N.A.	Cardiotoxicity	Genotypes AG + GG are not associated with exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype AA.		[ 11]
Genetic Polymorphism	rs11075291
Site of GPD	chr16:16004618 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>T
Minor Allele Frequency	G=0.5490/1086 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Lymphopenia	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.		[ 8]
Allele A	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Antineoplastic Agents	N.A.	Drug Toxicity	Allele A is not associated with risk of Drug Toxicity when treated with antineoplastic agents and corticosteroids in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 9]
Corticosteroids	N.A.	Drug Toxicity	Allele A is not associated with risk of Drug Toxicity when treated with antineoplastic agents and corticosteroids in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 9]
Genetic Polymorphism	rs1967120
Site of GPD	chr16:16015037 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	G=0.4470/884 (Global)
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Irinotecan	N.A.	Neutropenia	Genotypes AA + AG are not associated with severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype GG.		[ 11]
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Vincristine	N.A.	Neurotoxicity Syndromes	Allele G is associated with decreased likelihood of Neurotoxicity Syndromes when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 24]
Genetic Polymorphism	rs35626
Site of GPD	chr16:16076758 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>T
Minor Allele Frequency	G=0.5780/1143 (Global)
Genotypes GT + TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Irinotecan	N.A.	Neutropenia	Genotypes GT + TT are not associated with severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype GG.		[ 11]
Genetic Polymorphism	rs152023
Site of GPD	chr16:15991379 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.4300/850 (Global)
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Irinotecan	N.A.	Neutropenia	Genotypes CT + TT are not associated with severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype CC.		[ 11]
Genetic Polymorphism	rs12934692
Site of GPD	chr16:16006656 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>G / C>T
Minor Allele Frequency	C=0.5680/1124 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele T is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele C.		[ 25]
Genetic Polymorphism	rs4148333
Site of GPD	chr16:15959872 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.4230/837 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele C is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele T.		[ 25]
Genetic Polymorphism	rs4781701
Site of GPD	chr16:15967085 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.8720/1725 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele C is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele T.		[ 25]
Genetic Polymorphism	rs3887893
Site of GPD	chr16:16111644 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C / T>G
Minor Allele Frequency	T=0.5860/1159 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele T is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele C.		[ 25]
Genetic Polymorphism	rs17501011
Site of GPD	chr16:15987266 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.9800/1939 (Global)
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Folfiri	N.A.	Overall Survival	Genotypes AA + AG is associated with decreased overall survival when treated with FOLFIRI in people with Colorectal Neoplasms as compared to genotype GG.		[ 26]
Genetic Polymorphism	rs35529209
Site of GPD	chr16:16111468 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=1.0000/1979 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Conjugated Estrogens	N.A.	Neurotoxicity Syndromes	Allele A is associated with decreased transport of conjugated estrogens.		[ 27]
Genetic Polymorphism	rs4148356
Site of GPD	chr16:16083418 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.9770/1933 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Conjugated Estrogens	N.A.	Neurotoxicity Syndromes	Allele A is associated with decreased transport of conjugated estrogens.		[ 27]
Genetic Polymorphism	rs17287570
Site of GPD	chr16:16061246 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C
Minor Allele Frequency	A=0.8700/1721 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Irinotecan	N.A.	Neurotoxicity Syndromes	Allele A is associated with decreased likelihood of severe myelosuppression when treated with irinotecan in people with Neoplasms as compared to allele C.		[ 28]
Genetic Polymorphism	rs8187843
Site of GPD	chr16:16008018 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C / G>T
Minor Allele Frequency	G=0.9810/1941 (Global)
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
SN-38	N.A.	Neurotoxicity Syndromes	Genotypes AA + AG are not associated with exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype GG.		[ 11]
References
1	Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med. 2006 Feb 15;173(4):379-85.
2	Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer. 2013 Aug;60(8):1375-81.
3	Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012 May 1;30(13):1422-8.
4	Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J. 2014 Jun;14(3):241-7.
5	The GSTA1 polymorphism and cyclophosphamide therapy outcomes in lupus nephritis patients. Clin Immunol. 2015 Oct;160(2):342-8.
6	NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005 Dec 13;112(24):3754-62.
7	Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. Sci Rep. 2018 May 9;8(1):7342.
8	A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial. J Clin Pharmacol. 2018 Dec;58(12):1541-1549.
9	Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol. Pharmacogenomics J. 2017 Jan;17(1):4-10.
10	Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol. 2008 Aug;128(8):1925-9.
11	ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. Pharmacogenomics J. 2018 Jan;18(1):35-42.
12	ABCB1 and ABCC1 variants associated with virological failure of first-line protease inhibitors antiretroviral regimens in Northeast Brazil patients. J Clin Pharmacol. 2013 Dec;53(12):1286-93.
13	ABCC1, ABCG2 and FOXP3: Predictive Biomarkers of Toxicity from Methotrexate Treatment in Patients Diagnosed with Moderate-to-Severe Psoriasis. Biomedicines. 2023 Sep 19;11(9).
14	Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted? Int J Mol Sci. 2015 Jun 16;16(6):13760-80.
15	Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease. Haematologica. 2015 Feb;100(2):275-83.
16	Fentanyl dosage for preterm infants suggested by a pharmacokinetic, -dynamic, and -genetic model. Pediatr Res. 2025 Jan;97(1):239-245.
17	Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes. Clin Pharmacol Ther. 2019 Feb;105(2):402-410.
18	A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J. 2013 Oct;13(5):403-9.
19	Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021 May;68(5):e28858.
20	Impact of Genetic Polymorphisms on 6-Thioguanine Nucleotide Levels and Toxicity in Pediatric Patients with IBD Treated with Azathioprine. Inflamm Bowel Dis. 2015 Dec;21(12):2897-908.
21	Clinical and genetic risk factors for the prediction of hepatotoxicity induced by a docetaxel, epirubicin and cyclophosphamideregimen in breast cancer patients. Pharmacogenomics. 2021 Jan;22(2):87-98.
22	Association between genetic variants of membrane transporters and the risk of high-grade hematologic adverse events in a cohort of Mexican children with B-cell acute lymphoblastic leukemia. Front Oncol. 2023;13:1276352.
23	ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine. Pharmgenomics Pers Med. 2017;10:235-242.
24	Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia. Pharmacogenomics. 2016 May;17(7):731-41.
25	Association of ABCC Gene Polymorphism With Susceptibility to Antituberculosis Drug-Induced Hepatotoxicity in Western Han Patients With Tuberculosis. J Clin Pharmacol. 2020 Mar;60(3):361-368.
26	Combination of germline variations associated with survival of folinic acid, fluorouracil and irinotecan-treated metastatic colorectal cancer patients. Pharmacogenomics. 2019 Nov;20(17):1179-1187.
27	Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1). Pharmacogenet Genomics. 2005 Sep;15(9):647-57.
28	Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression. J Hum Genet. 2009 Oct;54(10):572-80.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.